Editorial: FDA restrictions threaten legacy drugs

The FDA in June began to mandate that unapproved legacy drugs, such as quinine, must undergo the same approval process that new drugs go through as part of the agency's new strategy to improve drug safety. These types of longstanding drugs could be withdrawn for the market unless they submit to the FDA's expensive new drug application process, leading The Wall Street Journal to call for the FDA to give them a "special regulatory pathway" for approval.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL